Your browser is no longer supported. Please, upgrade your browser.
Settings
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.27 Insider Own2.50% Shs Outstand48.32M Perf Week5.06%
Market Cap1.10B Forward P/E- EPS next Y-2.86 Insider Trans-2.32% Shs Float47.27M Perf Month3.77%
Income-108.30M PEG- EPS next Q-0.63 Inst Own83.40% Short Float17.88% Perf Quarter0.97%
Sales30.10M P/S36.65 EPS this Y21.80% Inst Trans5.06% Short Ratio11.49 Perf Half Y-8.50%
Book/sh4.45 P/B5.13 EPS next Y- ROA-27.40% Target Price46.71 Perf Year-44.33%
Cash/sh7.08 P/C3.23 EPS next 5Y- ROE-47.60% 52W Range17.80 - 40.11 Perf YTD0.35%
Dividend- P/FCF- EPS past 5Y- ROI-42.30% 52W High-45.25% Beta2.36
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin- 52W Low23.37% ATR0.97
Employees133 Current Ratio8.50 Sales Q/Q-46.20% Oper. Margin- RSI (14)45.63 Volatility4.15% 4.16%
OptionableYes Debt/Eq0.00 EPS Q/Q11.00% Profit Margin- Rel Volume0.60 Prev Close22.83
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume735.24K Price21.96
Recom- SMA201.14% SMA50-6.59% SMA200-13.15% Volume372,258 Change-3.81%
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Jun-15-19 11:30AM  Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association GlobeNewswire
Jun-14-19 09:00AM  Glaxo Inks Genome Research Deal With University of California Zacks
Jun-11-19 06:00AM  Is the Newest Gene Editing Stock a Buy? Motley Fool
Jun-10-19 09:29AM  CRISPR Therapeutics Up on Collaboration Expansion by Vertex Zacks
Jun-07-19 07:45AM  Why I'm Sticking With My 3 Worst-Performing Stocks of 2019 So Far Motley Fool +8.89%
Jun-06-19 09:17AM  Life sciences VC firm Third Rock raises $770M in its largest round ever American City Business Journals
May-20-19 04:14PM  Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study Zacks
May-19-19 10:58PM  Edited Transcript of EDIT earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-17-19 06:00AM  3 Small-Cap Biotech Stocks You Can Buy Right Now Motley Fool
May-10-19 10:11AM  Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil Zacks
May-09-19 03:03PM  IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus Zacks
May-08-19 05:28PM  Editas Gears Up for a Busy 2019 Motley Fool
12:23AM  Editas Medicine, Inc. (EDIT) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:05PM  Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:57PM  Editas: 1Q Earnings Snapshot Associated Press
04:01PM  Editas Medicine Announces First Quarter 2019 Results and Update GlobeNewswire
06:01AM  After $59M round, CRISPR startup launches with plans to tackle heart disease American City Business Journals
May-06-19 09:58AM  Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up Zacks
09:44AM  ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1 Zacks
May-03-19 03:40PM  Did Changing Sentiment Drive Editas Medicine's (NASDAQ:EDIT) Share Price Down By 27%? Simply Wall St.
09:30AM  Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? Zacks
09:24AM  Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT) Insider Monkey
May-02-19 04:26PM  Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy? Insider Monkey
Apr-30-19 04:01PM  Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update GlobeNewswire -5.79%
Apr-29-19 09:19AM  Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10) GlobeNewswire -5.37%
Apr-27-19 01:00PM  Better Buy: Editas Medicine vs. CRISPR Therapeutics Motley Fool
Apr-25-19 11:15AM  Is a Beat in Store for Editas (EDIT) This Earnings Season? Zacks
10:34AM  Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Apr-17-19 01:10PM  One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward GuruFocus.com -5.51%
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-16-19 02:39PM  Bain Capital raising another life sciences fund after $720M debut American City Business Journals
Apr-10-19 02:00PM  3 Top Small-Cap Stocks to Buy in April Motley Fool
Apr-09-19 03:33PM  These Cannabis and China ETFs are Leading the 2019 Rally Investopedia
10:33AM  How Editas Medicine Could Make You Better (and Richer) Motley Fool
09:53AM  5 Stocks in the Age of Miracles Motley Fool
Apr-07-19 02:00PM  3 Top Small-Cap Biotech Stocks for Aggressive Investors Motley Fool
Apr-04-19 03:39PM  Editas (EDIT) Inks Cross Licensing Agreement with BlueRock Zacks
10:33AM  Why Editas Medicine Stock Popped 18.5% in March Motley Fool
Apr-03-19 04:11PM  CRISPR Biotech Inks Deal To Use Stem Cells In Gene-Editing Medicine Investor's Business Daily
09:15AM  Stocks Hold Onto Gains in Quiet Session Zacks
07:00AM  Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms GlobeNewswire
Mar-26-19 07:16AM  Better Buy: Editas Medicine vs. Sangamo Therapeutics Motley Fool
07:10AM  Research Report Identifies Spirit Airlines, Integrated Device Technology, Editas Medicine, MACOM Technology Solutions, Taylor Morrison Home, and Brunswick with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-21-19 06:13AM  Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons InvestorPlace
Mar-18-19 12:38PM  What Do Investors Need To Know About Editas Medicine, Inc.s (NASDAQ:EDIT) Earnings Outlook? Simply Wall St.
Mar-12-19 06:00AM  3 Stocks That Could Double Your Money Motley Fool
Mar-07-19 02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
Mar-04-19 06:01PM  Edited Transcript of EDIT earnings conference call or presentation 28-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
09:15AM  S&P Reclaims 2800; NASDAQs Streak Hits 10 Weeks Zacks
Mar-01-19 06:47PM  Why Editas Medicine Stock Soared Today Motley Fool +14.59%
03:20PM  A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements ETF Trends
08:00AM  Editas Medicine Prepares to Make History With EDIT-101 Motley Fool
Feb-28-19 11:22PM  Editas Medicine Inc (EDIT) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update GlobeNewswire
09:00AM  Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day® GlobeNewswire
Feb-27-19 09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
07:19AM  Editas (EDIT) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-26-19 10:54AM  CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study Zacks
08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
Feb-24-19 10:16AM  Better Buy: Editas Medicine vs. Intellia Therapeutics Motley Fool
Feb-21-19 04:02PM  Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results GlobeNewswire
Feb-14-19 05:45PM  Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know Zacks
12:01PM  Is Moderna a Buy? Motley Fool
Feb-09-19 10:03AM  Should Sangamo's Failure Make CRISPR Investors Nervous? Motley Fool
Feb-08-19 05:45PM  Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know Zacks
Feb-06-19 09:00AM  Editas Medicine Names David Scadden, M.D., to Board of Directors GlobeNewswire
Feb-01-19 05:45PM  Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know Zacks
01:53PM  3 Biotech Stocks That Are Set for a Breakthrough InvestorPlace
Jan-30-19 11:07AM  How Many Insiders Bought Editas Medicine, Inc. (NASDAQ:EDIT) Shares? Simply Wall St.
Jan-25-19 05:45PM  Editas Medicine (EDIT) Gains But Lags Market: What You Should Know Zacks
Jan-24-19 07:35AM  Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire +6.12%
Jan-23-19 08:18AM  Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool
07:55AM  Today's Research Reports on Trending Tickers: Editas Medicine and argenx ACCESSWIRE
Jan-22-19 04:28PM  Editas CEO Resigns Sending All 3 CRISPR Stocks Into Free Fall Investor's Business Daily -19.85%
11:38AM  Why Editas Medicine Is Crashing Today Motley Fool
11:06AM  Editas stock down 21% after announcing CEO departure MarketWatch
10:47AM  Gene-Editing Stocks Plunge on Editas CEO Exit, Crispr Downgrade Bloomberg
10:24AM  Editas CEO to step down amid management turnover at gene-editing firm American City Business Journals
09:00AM  Editas Medicine Announces Chief Executive Officer Transition GlobeNewswire
Jan-21-19 11:00AM  Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10) GlobeNewswire
Jan-18-19 05:45PM  Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know Zacks
12:55PM  4 Gene-Editing Technologies That Could Replace CRISPR Motley Fool
Jan-15-19 07:50AM  Today's Research Reports on Trending Tickers: Exelixis and Editas Medicine ACCESSWIRE +5.64%
Jan-11-19 05:50PM  Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know Zacks
Jan-10-19 06:05PM  Here's Why Editas Medicine Lost 16.6% in December Motley Fool
03:36PM  The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29% Motley Fool
08:15AM  4 Reasons Editas Medicine's Future Looks Really Bright Motley Fool
Jan-09-19 11:21AM  CRISPR cadre: Check out the 12 Mass. companies exploring gene editing American City Business Journals
Jan-08-19 04:33PM  Editas CEO Katrine Bosley: We take the responsibility of ... CNBC Videos
04:30PM  Radius Exceeds 2018 Financial Guidance, Provides Updates Zacks
09:54AM  Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks
09:30AM  Has Editas Medicine (EDIT) Outpaced Other Medical Stocks This Year? Zacks
08:16AM  Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day Zacks
06:01AM  Bull of the Day: Editas Medicine (EDIT) Zacks
Jan-07-19 04:57PM  Aerie's Rhopressa Succeeds in Study on Japanese Patients Zacks +7.46%
10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks
09:00AM  Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-19 06:29PM  Jazz Inks Deal with Codiak to Develop Exosome Therapeutics Zacks +5.65%
04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily
Jan-03-19 09:30AM  Novo Nordisk Boasts Strong Diabetes Presence and Pipeline Zacks -5.91%
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myer VickeshChief Technology OfficerMar 18Option Exercise0.653,0001,9503,000Mar 20 04:02 PM
Myer VickeshChief Technology OfficerMar 18Sale24.503,00073,5000Mar 20 04:02 PM
Hopfield JessicaDirectorMar 05Buy23.9410,200244,18816,900Mar 07 04:02 PM
Myer VickeshChief Technology OfficerFeb 20Option Exercise0.653,0001,9503,000Feb 22 04:11 PM
Myer VickeshChief Technology OfficerFeb 20Sale20.423,00061,2600Feb 22 04:11 PM
Hack Andrew A. F.Chief Financial OfficerFeb 04Option Exercise6.486,89544,6806,895Feb 06 04:41 PM
Hack Andrew A. F.Chief Financial OfficerFeb 04Sale21.396,895147,4840Feb 06 04:41 PM
Myer VickeshChief Technology OfficerJan 18Option Exercise11.214,00044,8404,000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 18Sale26.504,000106,0000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 17Option Exercise0.653,0001,9503,000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 17Sale26.183,00078,5400Jan 18 08:58 PM
Bosley KatrinePresident and CEOJan 08Sale25.2712,000303,2401,204,966Jan 10 04:11 PM
Hack Andrew A. F.Chief Financial OfficerJan 04Option Exercise6.487,00045,3607,000Jan 08 05:36 PM
Hack Andrew A. F.Chief Financial OfficerJan 04Sale22.487,000157,3600Jan 08 05:36 PM
Myer VickeshChief Technology OfficerDec 18Option Exercise11.214,00044,8404,000Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 18Sale27.414,000109,6400Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 17Option Exercise0.653,0001,9503,000Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 17Sale27.893,00083,6630Dec 19 04:41 PM
Bosley KatrinePresident and CEODec 03Sale31.9212,000383,0871,216,966Dec 06 04:02 PM
Hack Andrew A. F.Chief Financial OfficerNov 23Option Exercise6.485,28434,2405,284Nov 27 04:25 PM
Hack Andrew A. F.Chief Financial OfficerNov 23Sale28.155,284148,7390Nov 27 04:25 PM
Myer VickeshChief Technology OfficerNov 20Option Exercise11.214,00044,8404,000Nov 21 04:03 PM
Myer VickeshChief Technology OfficerNov 20Sale26.504,000106,0000Nov 21 04:03 PM
Myer VickeshChief Technology OfficerNov 19Option Exercise0.653,0001,9502,700Nov 21 04:03 PM
Myer VickeshChief Technology OfficerNov 19Sale28.193,00084,5790Nov 21 04:03 PM
Bosley KatrinePresident and CEONov 01Sale26.8812,000322,5081,228,966Nov 05 05:42 PM
Hack Andrew A. F.Chief Financial OfficerOct 26Option Exercise6.486,00038,8806,000Oct 30 05:05 PM
Hack Andrew A. F.Chief Financial OfficerOct 26Sale25.706,000154,2000Oct 30 05:05 PM
Myer VickeshChief Technology OfficerOct 18Option Exercise11.214,00044,8404,000Oct 19 04:01 PM
Myer VickeshChief Technology OfficerOct 18Sale29.444,000117,7600Oct 19 04:01 PM
Myer VickeshChief Technology OfficerOct 17Option Exercise0.653,0001,9503,000Oct 19 04:01 PM
Myer VickeshChief Technology OfficerOct 17Sale28.873,00086,6100Oct 19 04:01 PM
Bosley KatrinePresident and CEOOct 01Sale31.0212,000372,2931,240,966Oct 03 04:03 PM
Hack Andrew A. F.Chief Financial OfficerSep 28Option Exercise6.488,00051,8408,000Oct 02 04:02 PM
Hack Andrew A. F.Chief Financial OfficerSep 28Sale32.088,000256,6400Oct 02 04:02 PM
Myer VickeshChief Technology OfficerSep 18Option Exercise11.214,00044,8404,000Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 18Sale32.194,000128,7600Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 17Option Exercise0.653,0001,9503,000Sep 19 04:03 PM
Myer VickeshChief Technology OfficerSep 17Sale32.333,00096,9900Sep 19 04:03 PM
Bosley KatrinePresident and CEOSep 04Sale32.3512,000388,2101,252,966Sep 06 04:02 PM
Hack Andrew A. F.Chief Financial OfficerAug 31Option Exercise6.4810,00064,80010,000Sep 05 04:04 PM
Hack Andrew A. F.Chief Financial OfficerAug 31Sale32.2310,000322,3000Sep 05 04:04 PM
Myer VickeshChief Technology OfficerAug 20Option Exercise11.214,00044,8403,600Aug 21 04:09 PM
Bosley KatrinePresident and CEOAug 20Sale30.1712,000362,0081,264,966Aug 22 04:16 PM
Myer VickeshChief Technology OfficerAug 20Sale29.874,000119,4800Aug 21 04:09 PM
Myer VickeshChief Technology OfficerAug 17Option Exercise0.653,0001,9503,000Aug 21 04:09 PM
Myer VickeshChief Technology OfficerAug 17Sale29.653,00088,9500Aug 21 04:09 PM
Bosley KatrinePresident and CEOAug 01Sale29.558,333246,2531,276,966Aug 03 04:01 PM
Myer VickeshChief Technology OfficerJul 18Option Exercise11.217,00078,4706,150Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 18Sale35.567,000248,8920Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Option Exercise0.657,0004,5504,000Jul 19 04:07 PM
Myer VickeshChief Technology OfficerJul 17Sale35.717,000249,9800Jul 19 04:07 PM
Bosley KatrinePresident and CEOJul 02Sale36.298,333302,4411,285,299Jul 05 04:00 PM